| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Peter A Kiener is Director at CUE. Peter A Kiener's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $7K at current prices.
Our model assigns Peter A Kiener a strong insider score of 72/100, based on 3 past trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +66.6%.
The CUE filings lean toward selling, a net 29,501 shares.
Peter A Kiener has 18 Form 4 filings on record from June 2018 to January 2026, across 2 companies: Director at Cue Biopharma (CUE), 2018–2026; Director at Palvella Therapeutics (PVLA), 2018–2023.
The 21 reported transactions were 15 option or other derivative awards, 3 option exercises and 3 open-market sales.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $392K.
The largest open-market sale was 20,176 shares of CUE at an average $17.93 on November 16, 2021, about $362K. Twelve months later CUE was down 78%.